Michael Makris: I Believe the Time Has Come to Consider Emicizumab Up Front in Persons with Acquired Hemophilia
Michael Makris, Emeritus Professor of Haemostasis and Thrombosis at the University of Sheffield, Editor-in-Chief of RPTH Journal, shared on LinkedIn:
”I believe the time has come to consider emicizumab up front in persons with acquired hemophilia.
I was unsure initially, but all the data is pointing in the right direction.
A German study in the current issue of Blood Advances confirms the value of early emicizumab in acquired hemophilia.
This was not a randomised study, but I feel it will be challenging to do a randomised trial here. The data from Germany, Japan, and the US are consistent.
Emicizumab prevents bleeds whilst immunosuppression is given a chance to work.
The last time I asked, I was told that Roche was not intending to get emicizumab approved in Europe for acquired hemophilia.
If approval and an RCT are not coming, what are we waiting for before considering emicizumab up front in acquired hemophilia?”
Read the full article here.
Article: Sustained survival benefit of emicizumab and postponed immunosuppression in acquired hemophilia A
Authors: Inga M. Schimansky, Christiane Dobbelstein, Robert Klamroth, Christina Hart, Ulrich J. Sachs, Richard Greil, Paul Knöbl, Johannes Oldenburg, Wolfgang Miesbach, Christian Pfrepper, Karolin Trautmann-Grill, Patrick Möhnle, Katharina Holstein, Hermann Eichler, Sonja Werwitzke, Andreas Tiede
Stay updated on all scientific advances with Hemostasis Today.
-
Nov 27, 2025, 16:00Nathan Connell on WFH AI Summaries from the Global Forum
-
Nov 27, 2025, 15:49Piotr Czempik: Rethinking Coagulation in Acute Liver Dysfunction
-
Nov 27, 2025, 15:35Overwhelmed? A Leader’s Guide from Mark Crowther to Getting Back on Track
-
Nov 27, 2025, 15:10Wolfgang Miesbach’s Top 10 Picks for TTP and Thrombosis from ASH 2025
-
Nov 27, 2025, 14:24ICCBBA’s Executive Director Eoin McGrath Chairs a Dynamic Session on AI, Innovation and Informatics in Transfusion Medicine
-
Nov 27, 2025, 13:26Wolfgang Miesbach’s Top 10 Picks for Bleeding Disorders from ASH 2025
-
Nov 27, 2025, 11:19Priya Prasad Presents a Case of Severe Hypotensive Transfusion Reaction
-
Nov 27, 2025, 04:07Eugene Tang Presents Highlights from UK Stroke Forum 2025
-
Nov 27, 2025, 03:30Stefan Gerner on Safety of Tenecteplase Versus Alteplase for IVT